SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- cardiovascular -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (193)4/29/2010 4:59:37 AM
From: idos  Respond to of 214
 
Yes, Zetia's mechanism for lowering LDL levels is different from the statins (inhibition of production in the liver by a statin vs. inhibition of absorption by Zetia).



To: DewDiligence_on_SI who wrote (193)4/29/2010 7:47:02 AM
From: idos  Respond to of 214
 
In addition to my previous reply, I think that by new potential molecular targets for the therapy Eicke Latz probably meant the NLRP3 inflammasomes,